on 20 Sep 2022
Last Applicant/ Owned by
RM 802, 8F, 1BLD, WEST TOWER, 88,
SHANGHAI
CN
201210
Serial Number
88519029 filed on 17th Jul 2019
Registration Number
6852814 registered on 20th Sep 2022
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
Monoclonal antibodies for use in disease testing; biological preparations for the treatment of cancer; tumor suppressing agents; anti-cancer preparations; pharmaceutical preparations for the treatment of immune system related diseases and disorders Biomedical research services; conducting early evaluations in the field of new pharmaceuticals; quality control of goods and services; product quality Read More
Monoclonal antibodies for use in disease testing; biological preparations for the treatment of cancer; tumor suppressing agents; anti-cancer preparations; pharmaceutical preparations for the treatment of immune system related diseases and disorders
21st Dec 2020
21st Dec 2020
Biomedical research services; conducting early evaluations in the field of new pharmaceuticals; quality control of goods and services; product quality testing; pharmaceutical product evaluation; biological research; conducting clinical trials for others that feature or contain monoclonal antibodies; research and development services in the field of antibodies
13th Apr 2020
28th Apr 2020
No 88519029
No Service Mark
No 54LW-301328
No
No
No
No
No
No
No
No
28.01.03 -
Japanese and Chinese characters Formerly Inscriptions in Chinese, Japanese, Korean, Vietnamese or other Asian characters
Status Date | Action Taken |
---|---|
17th May 2023 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
20th Sep 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
20th Sep 2022 | REGISTERED-PRINCIPAL REGISTER |
16th Aug 2022 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
15th Aug 2022 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
12th Aug 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
12th Aug 2022 | STATEMENT OF USE PROCESSING COMPLETE |
27th Jul 2022 | TEAS STATEMENT OF USE RECEIVED |
27th Jul 2022 | USE AMENDMENT FILED |
01st Feb 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |